Cognition Therapeutics, Inc (简称Cognition)宣布，在收到美国食品药品监督管理局（FDA）的正式会议纪要后，公司已就其核心候选药物Zervimesine (CT1812)用于治疗路易体痴呆（DLB）相关精神病的关键性研究的关键方面与监管机构达成一致。这一进展标志着该药物研发路径上的一个重要里程碑。公司表示，将基于这些共识，推进后续临床研究计划，旨在为这一严重未满足医疗需求的领域提供新的治疗选择。
Cognition Therapeutics, Inc (简称Cognition)宣布，在收到美国食品药品监督管理局（FDA）的正式会议纪要后，公司已就其核心候选药物Zervimesine (CT1812)用于治疗路易体痴呆（DLB）相关精神病的关键性研究的关键方面与监管机构达成一致。这一进展标志着该药物研发路径上的一个重要里程碑。公司表示，将基于这些共识，推进后续临床研究计划，旨在为这一严重未满足医疗需求的领域提供新的治疗选择。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.